Regeneron Pharmaceuticals Inc vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B), while Direxion Daily S&P 500 Bull 3X Shares trades at $283.48. The key difference: Regeneron Pharmaceuticals Inc pays a 0.46% dividend while Direxion Daily S&P 500 Bull 3X Shares pays none. Which is the better fit depends on your goals.
| REGN | SPXL | |
|---|---|---|
Market Cap | $83.43B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $852.03 | $301.38 |
52-Week Low | $555.51 | $170.20 |
Enterprise Value | $78.14B | — |
Dividend Yield | 0.46% | — |
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
SPXL, a leveraged ETF tracking the S&P 500, trades at $285.5, down 1.67% amid broader market caution. Technical indicators show a neutral overall signal with bullish moving averages, while support sits at $284 and resistance at $289. Recent news highlights market resilience despite geopolitical tensions and high valuations, with the S&P 500 up 13% over six months amid Iran conflicts.
The outlook remains mixed: AI-driven earnings growth supports further gains, but elevated valuations and Fed rate risks pose headwinds. Investors face volatility from oil prices and trade policies, yet long-term index fund strategies are favored by analysts targeting S&P 500 levels near 8,000.
Trailing returns across standard periods
Latest headlines on both assets
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →